Trial Profile
A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibalizumab (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- 25 Oct 2020 Results (n=12) assessing long-term efficacy, safety and durability of Ibalizumab in a sub-group of patients who received treatment for an average of nine years presented at the IDWeek 2020
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.